https://www.businesswire.com/news/home/20180724005989/en/ > WASHINGTON & SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--Jul 24, 2018--California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, today applauded the U.S. House passage of H.R. 184, the Protect Medical Innovation Act, which permanently repeals the job and innovation hindering 2.3% medical device excise tax levied on medical technology companies. The bill now awaits U.S. Senate action. This statement can be attributed to Sara Radcliffe, President & CEO, California Life Sciences Association: > “California Life Sciences Association (CLSA) applauds the U.S. House passage of H.R. 184, legislation that permanently cancels the ill-conceived 2.3% medical device tax, so that it cannot further hinder innovation and investment in medical technology research and development.